Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.

@article{Oster2022MyocarditisCR,
  title={Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.},
  author={Matthew E. Oster and David K. Shay and John R Su and Julianne M Gee and Clarence Buddy Creech and Karen R. Broder and Kathryn M. Edwards and Jonathan H. Soslow and Jeffrey M. Dendy and Elizabeth P Schlaudecker and Sean M. Lang and Elizabeth D. Barnett and Frederick L. Ruberg and Michael John Smith and Michael J. Campbell and Renato Delascio Lopes and Laurence S Sperling and Jane A Baumblatt and Deborah Thompson and Paige L. Marquez and Penelope Strid and Jared Woo and River A. Pugsley and Sarah Reagan‐Steiner and Frank Destefano and Tom T. Shimabukuro},
  journal={JAMA},
  year={2022},
  volume={327 4},
  pages={
          331-340
        }
}
Importance Vaccination against COVID-19 provides clear public health benefits, but vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID-19 vaccination are unclear. Objective To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US. Design, Setting, and Participants Descriptive study of reports of myocarditis to the Vaccine Adverse Event Reporting System (VAERS) that occurred after mRNA-based COVID-19… 

Figures and Tables from this paper

Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature
TLDR
Younger vaccinees more frequently report myocarditis and pericarditis following mRNA COVID-19 vaccines than older vaccinees, and results were consistent with the spontaneous report analyses.
Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations
TLDR
The findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine, which is higher after a second vaccine dose, higher in males than in females, and decreased with age.
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022
TLDR
Findings support continued use of mRNA COVID-19 vaccines among all eligible persons aged ≥5 years after SARS-CoV-2 infection and Multisystem inflammatory syndrome.
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
TLDR
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis in both adolescents and adults and Prospective follow-up of patients who have developed these complications after vaccination is required to assess long-term outcomes.
Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
TLDR
The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
TLDR
While the observed number of myocarditis cases was small, the number was higher than expected among male military members after a second vaccine dose, and must be considered in the context of the well-established risk of morbidity, including cardiac injury, following COVID-19 infection.
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
TLDR
Among patients in a large Israeli health care system who had received at least one dose of the BNT162b2 mRNA vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons; the highest incidence was among male patients between the ages of 16 and 29 years.
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
TLDR
ACIP determined that the benefits of using mRNA COVID-19 vaccines under the FDA's EUA clearly outweigh the risks in all populations, including adolescents and young adults.
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination.
TLDR
Cardiac magnetic resonance imaging findings were found to be consistent with acute myocarditis in 7 patients; 4 of whom had preceding COVID-19 vaccination.
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
TLDR
The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients, and was highest in male recipients between the ages of 16 and 19 years.
Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021
TLDR
COVID-19 was significantly associated with an increased risk for myocarditis, with risk varying by age group, and the importance of implementing evidence-based CO VID-19 prevention strategies, including vaccination, to reduce the public health impact of COvid-19 and its associated complications.
Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
TLDR
No causal relationship between vaccine administration and myocarditis has been established, and Continued monitoring and reporting to the US Food and Drug Administration Vaccine Adverse Event Reporting System is strongly recommended.
Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.
TLDR
Among US military personnel vaccinated against smallpox, myopericarditis occurred at a rate of 1 per 12 819 primary vaccinees, higher than the expected rate among personnel who were not vaccinated.
...
...